Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor and Clofarabine in Older Adults with AML
NCT01160354Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2010
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Aug 2010; status: terminated.
02
Drugs
plerixafor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01160354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160354.